Talditercept alfa API Manufacturers
compare suppliers & get competitive offers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Talditercept alfa is listed?
Join our notification list by following this page.
Join our notification list by following this page.
List your company
Are you a supplier of Talditercept alfa or other APIs and are you looking to list your company on Pharmaoffer?
Click the button below to find out more
Click the button below to find out more
Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?
Click the button below to switch over to the contract services area of Pharmaoffer.
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Talditercept alfa API 1580555-26-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Talditercept alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Talditercept alfa
- Synonyms:
- Adnectin, anti-(human growth differentiation factor 8) (synthetic clone prd-1474 fibronectin type iii tenth domain (10fn3)-based isoform , Bivalent Anti-Human Myostatin Adnectin-Igg1 , Bms-986089 (fully human anti-myostatin adnectin) , Immunoglobulin g1 (human fc fragment) fusion protein with peptide (synthetic 17-amino acid linker) fusion protein with adnectin, anti-(human growth differentiation factor 8) (human clone bms-986089 fibronectin tenth type iii domain-derived), dimer , Taldefgrobep alfa , Talditercept alfa
- Cas Number:
- 1580555-26-5
- DrugBank number:
- DB16337
- Unique Ingredient Identifier:
- 766C38JSAR
General Description:
Talditercept alfa, identified by CAS number 1580555-26-5, is a notable compound with significant therapeutic applications. Talditercept alfa is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).
